SCHEMBL6481209

SCHEMBL6481209

C[C@@H]1[C@@H](c2ccccc2)NC(=O)N1C(=O)NC1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.46
HPGD P15428 1/20 0.46
GAA P10253 1/20 0.44
P2RX1 P51575 1/20 0.44
P2RX3 P56373 1/20 0.44
P2RX4 Q99571 1/20 0.44
P2RX7 Q99572 1/20 0.44
CNR1 P21554 4/20 0.43
CNR2 P34972 4/20 0.43
NPSR1 Q6W5P4 2/20 0.43
HTT P42858 1/20 0.43
BCHE P06276 1/20 0.43
PKM P14618 1/20 0.43
RAB9A P51151 3/20 0.43
EPHX2 P34913 2/20 0.43
EPHX1 P07099 1/20 0.43
TSHR P16473 1/20 0.42
NPC1 O15118 1/20 0.42
POLB P06746 1/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6481211 1.00 SMN1; SMN2 (0.46) SMN1; SMN2HPGDGAAP2RX1P2RX3
SCHEMBL6481214 1.00 SMN1; SMN2 (0.46) SMN1; SMN2HPGDGAAP2RX1P2RX3
SCHEMBL10718544 0.79 GAA (0.52) SMN1; SMN2HPGDGAAP2RX1P2RX3
SCHEMBL6495108 0.78 TSHR (0.45) SMN1; SMN2HPGDGAAP2RX1P2RX3
SCHEMBL11033360 0.78 SMN1; SMN2 (0.44) SMN1; SMN2HPGDGAAP2RX1P2RX3
SCHEMBL11103830 0.78 SMN1; SMN2 (0.44) SMN1; SMN2HPGDGAAP2RX1P2RX3
SCHEMBL6495106 0.78 TSHR (0.45) SMN1; SMN2HPGDGAAP2RX1P2RX3
SCHEMBL11103826 0.78 SMN1; SMN2 (0.44) SMN1; SMN2HPGDGAAP2RX1P2RX3
SCHEMBL6495111 0.78 TSHR (0.45) SMN1; SMN2HPGDGAAP2RX1P2RX3
Chlorobenzene SCHEMBL9597816 0.70 CNR1 (0.43) SMN1; SMN2P2RX1P2RX3P2RX4P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032858-A1 Novel heterocyclic compound and anti-inflamatory agent NIPPON SODA CO., LTD. (JP) 2005-02-10 US disclosed
EP-1435353-A1 NOVEL HETEROCYCLIC COMPOUND AND ANTI-INFLAMMATORY AGENT NIPPON SODA CO., LTD. (JP) 2004-07-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032858-A1 Novel heterocyclic compound and anti-inflamatory agent TLR5, IRF3, IL4 SMN1; SMN2 2638/4885HPGD 440/4885GAA 3972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.